Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct;10(10):975-80.
doi: 10.1016/S1470-2045(09)70227-X.

Development of therapeutic HPV vaccines

Cornelia L Trimble  1 , Ian H Frazer
Affiliations
Review

Development of therapeutic HPV vaccines

Cornelia L Trimble et al. Lancet Oncol. 2009 Oct.

Abstract

At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

IHF receives royalties from sales of HPV prophylactic vaccines, and is a consultant for Merck, GlaxoSmithKine, and Commonweath Serum Laboratories on papillomavirus vaccine development. CLT declared no conflicts of interests.

Figures

Figure
Figure
Identifying barriers to therapeutic vaccination for human papillomavirus disease
See this image and copyright information in PMC

References

    1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44. - PubMed
    1. Frazer IH, Lowy DR, Schiller JT. Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol. 2007;37 (suppl 1):S148–55. - PubMed
    1. HPV and cervical cancer in the 2007 report. Vaccine. 2007;25 (suppl 3):C1–230. - PubMed
    1. Hudson J, Bedell M, McCance D, Laiminis L. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol. 1990;64:519–26. - PMC - PubMed
    1. Li W, Wang W, Si M, et al. The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma. J Cancer Res Clin Oncol. 2008;134:1355–61. - PubMed

Publication types

MeSH terms